These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 18307682)

  • 1. Lower urinary tract symptoms and sexual dysfunction: a common approach.
    Giuliano F
    BJU Int; 2008 Mar; 101 Suppl 3():22-6. PubMed ID: 18307682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
    Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
    Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
    Wang C
    Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB; Myers JB; O'Donnell C; Crawford ED
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
    Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
    Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
    Gales BJ; Gales MA
    Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common approach to managing lower urinary tract symptoms and erectile dysfunction.
    Taylor JM; Desouza R; Wang R
    Asian J Androl; 2008 Jan; 10(1):45-53. PubMed ID: 18087643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation.
    Nickel JC; Elhilali M; Emberton M; Vallancien G;
    BJU Int; 2006 Jun; 97(6):1242-6. PubMed ID: 16686719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry.
    Rosen RC; Wei JT; Althof SE; Seftel AD; Miner M; Perelman MA;
    Urology; 2009 Mar; 73(3):562-6. PubMed ID: 19167031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of medical treatments for benign prostatic hyperplasia on sexual function.
    Giuliano F
    BJU Int; 2006 Apr; 97 Suppl 2():34-8; discussion 44-5. PubMed ID: 16507052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.